This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lawrence, T. S. Articles by Loney, T. L. Search for Related Content PubMed PubMed Citation Articles by Lawrence, T. S. Articles by Loney, T. L.

Fluoropyrimidine-mediated Radiosensitization Depends on Cyclin E-dependent Kinase Activation¹

Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109

Fluoropyrimidines radiosensitize human colon cancer cells that progress into S phase in the presence of drug (M. A. Davis, H-Y. Tang, J. Maybaum, and T. S. Lawrence. Int. J. Radiat. Biol. 67: 509–512, 1995). We hypothesized that progression occurs in cells that generate elevated levels of cyclin E-dependent kinase activity despite the presence of the fluoropyrimidine. To test this hypothesis, we treated HT29 and SW620 human colon cancer cells with fluorodeoxyuridine under conditions that produced nearly complete inhibition of thymidylate synthase but which sensitized only the HT29 cells. We found that, whereas HT29 cells progressed into S phase and demonstrated increased cyclin E-dependent kinase activity, SW620 cells arrested just past the G₁-S boundary and showed no change in kinase activity. Because these cell lines have the same p53 mutation, these findings suggest that there is a p53-independent G₁-S checkpoint that mediates radiosensitization produced by fluorodeoxyuridine.

¹ Supported by NIH grant R01 CA53440 and Cancer Center Core Grant CA46592.

² To whom requests for reprints should be addressed, at Department of Radiation Oncology, University of Michigan, 1331 E. Ann Street, Ann Arbor, Michigan 48109-0582; Phone: 313-936-7380; Fax: 313-763-1581; e-mail: tsl@umich.edu.

Received 4/ 9/96. Accepted 5/30/96.

This article has been cited by other articles:

				L. N. Kaliberova, D. L. Della Manna, V. Krendelchtchikova, M. E. Black, D. J. Buchsbaum, and S. A. Kaliberov Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene Mol. Cancer Ther., September 1, 2008; 7(9): 2845 - 2854. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]

				L. A. Parsels, J. D. Parsels, D. C.-H. Tai, D. J. Coughlin, and J. Maybaum 5-Fluoro-2'-Deoxyuridine-Induced cdc25A Accumulation Correlates with Premature Mitotic Entry and Clonogenic Death in Human Colon Cancer Cells Cancer Res., September 15, 2004; 64(18): 6588 - 6594. [Abstract] [Full Text] [PDF]

				H.-S. Hwang, T. W. Davis, J. A. Houghton, and T. J. Kinsella Radiosensitivity of Thymidylate Synthase-deficient Human Tumor Cells Is Affected by Progression through the G1 Restriction Point into S-Phase: Implications for Fluoropyrimidine Radiosensitization Cancer Res., January 1, 2000; 60(1): 92 - 100. [Abstract] [Full Text]